About Compass Pathways Plc
Compass Pathways (NASDAQ:CMPS) operates in the field of mental health care, specializing in developing innovative therapies to address a range of mental health conditions. The company is particularly focused on exploring the potential of psilocybin therapy for treatment-resistant depression, a significant and growing challenge in mental health care. Compass Pathways is actively engaged in clinical trials and research projects aimed at understanding and harnessing the therapeutic benefits of psychedelics. Their objective is to revolutionize the approach to mental health treatment, making effective and innovative therapies accessible to those in need. Compass Pathways is dedicated to improving patient outcomes and advancing mental health care through scientific research and development.
Snapshot
Operations
Produtos e/ou serviços de Compass Pathways Plc
- COMP360 (psilocybin therapy) is a synthetic psilocybin formulation for treatment-resistant depression (TRD).
- Digital therapeutic platforms support the deployment and scaling of COMP360, enriching patient experience and therapy outcomes.
- Strategic partnerships with academic and clinical institutions to advance psychedelic therapy research.
- Personalized therapy programs designed to work alongside COMP360, integrating patient-specific treatment approaches.
- Advanced training programs for therapists focusing on the delivery of psychedelic-assisted therapies, ensuring high-quality clinical support.
- Investment in innovative research on other psychedelic substances to expand their therapeutic portfolio beyond psilocybin.
equipe executiva do Compass Pathways Plc
- Mr. Kabir Kumar Nath M.A., M.B.A.CEO & Director
- Ms. Teri Loxam M.B.A.CFO, Principal Financial Officer & Principal Accounting Officer
- Dr. Guy GoodwinChief Medical Officer
- Dr. Greg Ryslik Ph.D.Chief Technology Officer
- Mr. Stephen D. SchultzSenior Vice President of Investor Relations
- Ms. Anne BenedictChief People Officer
- Mr. Lars Christian WildeSenior Advisor
- Dr. Susan C. Stansfield Ph.D.Advisor
- Dr. Michael Gold M.D., M.Sc.Chief Research & Development Officer
- Ms. Lori Englebert M.B.A.Chief Commercial Officer